We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

R(+)PPX High Dose Treatment of ALS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00600873
Recruitment Status : Completed
First Posted : January 25, 2008
Last Update Posted : September 13, 2010
Information provided by:
Bennett, James P., Jr., M.D., Ph.D.

Brief Summary:
R(+)pramipexole is administered in escalating doses to patients with early ALS. Plasma and spinal fluid levels of R(+)PPX are monitored, in addition to biochemical markers of oxidative stress.

Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Drug: R(+) pramipexole dihydrochloride monohydrate Phase 1 Phase 2

Expanded Access : Bennett, James P., Jr., M.D., Ph.D. has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.  

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Pharmacokinetics and Nitrative-Oxidative Stress Pharmacodynamics in Amyotrophic Lateral Sclerosis Subjects Taking Daily High-Dose R(+) Pramipexole Dihydrochloride for Six Months
Study Start Date : August 2007
Actual Primary Completion Date : September 2008
Actual Study Completion Date : January 2009

Arm Intervention/treatment
Experimental: 1
patients with early ALS
Drug: R(+) pramipexole dihydrochloride monohydrate
100 mg tid orally daily

Primary Outcome Measures :
  1. decline in ALSFRS score [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. plasma PPX levels [ Time Frame: 6 months ]
  2. CSF PPX levels [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • definite ALS no prior exposure to R(+)PPX

Exclusion Criteria:

  • ALSFRS at baseline <40 FVC at baseline <70%

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00600873

Layout table for location information
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
Bennett, James P., Jr., M.D., Ph.D.
Layout table for investigator information
Principal Investigator: Ted M Burns, MD University of Virginia
Publications of Results:
Layout table for additonal information
Responsible Party: James P. Bennett Jr. M.D. Ph.D. Sponsor, Virginia Commonwealth University
ClinicalTrials.gov Identifier: NCT00600873    
Other Study ID Numbers: 13023
First Posted: January 25, 2008    Key Record Dates
Last Update Posted: September 13, 2010
Last Verified: September 2010
Keywords provided by Bennett, James P., Jr., M.D., Ph.D.:
oxidative stress
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents